Company Update (NYSE:BSX): Boston Scientific Initiates Study Of Promus PREMIER™ Coronary Stent System In Underserved Patient Populations

[PR Newswire] – MARLBOROUGH, Mass., Oct. 20, 2014 /PRNewswire/ — As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation (BSX) has initiated the PLATINUM Diversity trial to evaluate . . . → Read More: Company Update (NYSE:BSX): Boston Scientific Initiates Study Of Promus PREMIER™ Coronary Stent System In Underserved Patient Populations Similar Articles: Company Update: Boston Scientific Corporation (NYSE:BSX) – Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging Market Update (NYSE:BSX): Boston Scientific Enrolls First Patients In U.S. Trial Of The Lotus™ Valve System Market Update: Boston Scientific Corporation (NYSE:BSX) – Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.